Targets › IL11
3 programs from 3 companies in 4 trials: 2 Phase 1, 2 Phase 2; Other, Respiratory, Oncology; next expected readout Dec 2026.
Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. Also promotes the proliferation of hepatocytes in response to liver damage. (UniProt, P20809)
Open in Phaseline: the race on IL11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 9MW3811 anti-IL-11 monoclonal antibody | IL11 | Phase 2 | Scar | Dec 2026 |
| Fudan University | rhG-CSF + rhIL-11 Recombinant granulocyte-colony stimulating factor combined with recombinant interleukin-11 | CSF3, IL11 | Phase 2 | Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) | Dec 2026 |
| Shanghai Huaota Biopharmaceutical | HB0056 Bispecific antibody targeting TSLP and IL-11 | TSLP, IL11 | Phase 1 | Healthy; Asthma | Aug 2027 |
Healthy (1) Asthma (1) Scar (1) Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) (1)
small molecule (3)
Shanghai Huaota Biopharmaceutical (1) Mabwell (Shanghai) Bioscience (1) Fudan University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.